Company Overview and News

5
3 Top Industrials 'Safer' Dividend WallStars Gain 40%-80.9% Per October Broker 2019 Targets

2018-10-12 seekingalpha - 1
WallStars are distinguished by positive broker target price upsides. 'Safer' dividend industrials WallStar one-yr. target gains for MSM, BGSF, HMLP, GMLP, DAL, CPA, MAN, CMRE, CPLP, and ATTO ranged from 12.82% to 80.92%.
ATTO CPLP HMLP MAN WM BGSF ETN CMRE GMLP CAJ EBF DAL

28
Top 10 Industrials WallStars Aim For 35%-80% Gains Per Broker October Targets

2018-10-11 seekingalpha
WallStars are distinguished by positive broker target price upsides. Atento led top yielding Industrial target gains with 90.92% calculated 10/9/18, by 8 analysts, while Golar LNG showed top WallStar yield.
LKSD CPLP HMLP DLNG PBOWP LKSD.WI PBOWN CMRE QUAD GEC GE ADES PBI TNP GLNG SFL PBI-B GMLP GNE USDP CYD

1
36% To 123% October Gains Targeted From 'Safer' Dividend 10%+ Yield Equities

2018-10-05 seekingalpha
Top 10 10%+ "Safer" Dividend WallStar annual yields ranged from 11.65% to 24.87%. Their free cash flow yields ranged from 13.01% to 77.86%.
CPLP SXCP ANH ORC EARN WMC SNMP TCRX DX NLY TCRD TCRZ TSLF GMLP GPP

11
Week Thoughts: Update From Zombieland

2018-10-01 seekingalpha
As if stuck on repeat, oil and natural gas were up, midstream was down this week. The S&P 500 paused its upward trajectory, and utilities were negative for a second straight week. Income securities had a rough month generally, and it feels like midstream is being painted with the "income stock" brush rather than the "energy stock" brush.
BKEP TGE AMID PAGP WGP SEP ANDX AM EQM NBLX EQGP OKE EEP FGP MPLX TLP ENLK GLNG SE ETP TCP GMLP DM WES SEMG

2
Capital Product Partners: Nearly 12% Yield With Growing Coverage And No K-1

2018-09-26 seekingalpha - 2
It is positioned in the product tanker sector, which is poised for rapidly improving rates as bullish 2020 regulations loom.
ASC CPLP KNOP GMLP HMLP GLOP DLNG PBR

12
Hoegh - An 8.5% Yield Which Is Well Covered

2018-09-25 seekingalpha - 1
As many readers know, I have been investing in shipping preferred stock for a while. I currently own positions in (capital structure positions listed - common, preferred or both) Costamare (CMRE) (CMRE.PC), Golar LNG (GMLPP), Seaspan Corp. (SSW.PH), Tsakos Energy (TNP.PD) and Teekay Offshore (TOO) (TOO.PE). Additionally, I own Teekay (TK) common.
TK HMLP SSW GLNG HOLHF SSWN TGP CMRE GMLP SSWA

 
The Hidden Jewel Behind This 17% Yield

2018-09-22 seekingalpha
The common yield is over 17%, but there's a much safer way to earn high-yield steady income.
GMLP GMLPP

 
The Safer High-Yield LNG Play: Hoegh LNG Partners

2018-09-21 seekingalpha
Hoegh LNG Partners LP (HMLP) is an extremely safe, high-yielding liquid natural gas investment. Its distribution is well-covered for many years due to long term and it has a strong future growth pipeline.
HMLP GMLP DLNG

4
Sanchez Midstream Tagged 'Safer' Dividend Follower Favorite Per Stockbroker September Surveys

2018-09-20 seekingalpha
From 8/15/18-9/17/18, Fredrik Arnold dividend "followers" commented on 40 equities and funds. Some comments were bad news, so some rogues mixed in to create a FollowerFavorite/Rogue (FoFa/Ro) list.
KWH.UN VOD VOD SXCP CRIUF ORC DVDDF CHMI CZZ CJREF CIM GMLP VODPF CJR.B CVX AVGO BRCM INTC SNMP

16
Fredrik Followers Favored 40 As Most Mentioned September Equities And Funds

2018-09-20 seekingalpha
August 15-September 17, Fredrik Arnold "followers" mentioned 40 equities & funds in their comments and suggestions. Some lamented bad news, so bad news investments mixed in with their favorites.
ARLP GIS AMID KWH.UN VOD VOD CRIUF ORC CNSL TYG CJREF CIM GMLP VODPF CJR.B CBL SNMP

16
Fredrik Followers Favored 40 As Most Mentioned September Equities & Funds

2018-09-20 seekingalpha
August 15-September 17, Fredrik Arnold "followers" mentioned 40 equities & funds in their comments and suggestions. Some lamented bad news, so bad news investments mixed in with their favorites.
ARLP GIS AMID KWH.UN VOD VOD CRIUF ORC CNSL TYG CJREF CIM GMLP VODPF CJR.B CBL SNMP

 
Golar LNG Partners: Improving Results, Potential Opportunity

2018-09-19 seekingalpha
Golar LNG Partners reported broadly improved numbers in the second quarter of 2018 compared to the first.
GMLP

1
15 'Safer' 10%+Yield Dividend WallStars Metamorphose In Mid-September

2018-09-19 seekingalpha
WallStars show positive broker target-price-upsides. 15 of 80 were tagged as "safer" for dividends because they showed positive one-year returns and free-cash-flow-yields greater than their dividend-yields 9/14/18.
CPLP SXCP ANH ORC SUN TWO SNMP TCRX DX NLY SFL TCRD TCRZ TSLF GMLP SIR GPP

3
Your 80 Mid-September 10%+ Dividend WallStars By Yield And Target Gains

2018-09-18 seekingalpha
WallStars have positive broker target price upsides. 80 stocks displayed 10%+ forward yield, $2.00+ prices, and $50M+ market caps as of 9/14/18. Yields above 12.2% narrowed the list to 30.
AMID AIC MMLP NAP PER HCLP CCLP AI GMLP MDLY AIW USDP SNMP

 
Golar LNG Partners LP: Market Fears Create Capital Gains And High Yield Opportunity

2018-09-18 seekingalpha
A recent series of events has eroded the coverage and management has cast doubt on maintaining the distribution level.
GMLP GLNG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: Y2745C102